ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
A phase 2 trial of Gotistobart, Pembrolizumab in ovarian cancer, run by OncoC4, Inc., active and no longer recruiting.
Overview
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT05446298 by OncoC4, Inc., with 58 participants enrolled, started 2022-12-22 and due to reach its primary completion in 2026-08-30. Interventions recorded: ONC-392, Pembrolizumab. Conditions listed: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
Setting
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Phase
Phase 2
Sponsor
OncoC4, Inc.
Registry
Enrolled
58
Similar pages
not linked directly; found by shared links- TrialONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Shares OncoC4, Gotistobart.
- TrialONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Shares OncoC4, Gotistobart.
- TrialSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Shares OncoC4, Gotistobart, Pembrolizumab.